RecruitingPhase 2NCT02523014
63
studies recruiting now
as of 7 Sept 2026
306
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
16 Aug 2024
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT04374305
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
RecruitingNCT00598351
Natural History Study of Patients With Neurofibromatosis Type 2
RecruitingNot applicableNCT06557512
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
RecruitingPhase 1NCT06014905
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 63 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Meningioma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Meningioma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (SMARCB1, PDGFB, SUFU, NF2, PIK3CA, AKT1).
Treatments being studied
20 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Mifepristone (Korlym)
Phase 3Magnesium Sulfate (Mag sulf)
Phase 2Ipilimumab (Yervoy)
Phase 2Vistusertib
Phase 2Dordaviprone
Phase 2Hydroxyurea (Droxia)
Phase 2Pembrolizumab (Keytruda)
Phase 2Abemaciclib (Verzenio)
+ 12 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).